JamesKManganMDPhD

Hematology • San Diego, CA

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Associate Clinical Professor of Medicine, University of California-San Diego

Join to view full profile

Dr. Mangan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mangan's full profile

Already have an account?

Office
200 W Arbor Dr
San Diego, CA 92103
Phone+1 800-926-8273

Fax+1 888-539-8781

Summary

Clinical care of patients with acute leukemia, chronic myeloid leukemia, MDS, MPNs, and aplastic anemia and allogeneic stem cell transplant for those disorders.

Clinical research in novel therapies for acute leukemias and myelodysplastic syndromes.

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2008 - 2011
University of MichiganResidency, Internal Medicine, 2005 - 2008
Lewis Katz School of Medicine at Temple UniversityClass of 2005

Certifications & Licensure

CA State Medical License 2019 - 2025
PA State Medical License 2008 - 2021
MI State Medical License 2005 - 2011
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis Start of enrollment: 2014 Jul 16
Active, not recruiting
Phase 1, Phase 2
Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox) Start of enrollment: 2014 Aug 01
Completed
Early Phase 1

Publications & Presentations

PubMed

46 citations
High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning
Ran Reshef, Austin P. Huffman, Amy Gao, Marlise R. Luskin, Noelle V. Frey
Journal of Clinical Oncology. 2015-06-08
58 citations
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.
Peter L Greenberg, Richard M Stone, Aref Al-Kali, John M Bennett, Uma Borate
Journal of the National Comprehensive Cancer Network. 2022-02-01
1 citations
Age-Adjusted Schedules of Venetoclax and Hypomethylating Agents to Treat Extremely Elderly Patients with Acute Myeloid Leukemia.
Aaron M Lee, Aaron M Goodman, James K Mangan
Case Reports in Hematology. 2022-01-01

Journal Articles

Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium Difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients
Edward A Stadtmauer, James K Mangan, Elizabeth O Hexner, David L Porter, Daria V Babushok, Jacqueline Smith, Craig W Freyer, Mindy Schuster, Noelle V Frey, Selina M Lu..., Clinical Infectious Diseases

Abstracts/Posters

Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
James K. Mangan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Drug Revumenib Achieves Complete Cancer Remission in 18 People with LeukemiaMarch 21st, 2023

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member

Other Languages

Spanish